Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04467489 · ClinicalTrials.gov registry record
Biomarkers of CASH
A clinical trial of Cerebral Cavernous Malformation and Cavernous Angioma, sponsored by University of Chicago.
- Active
- Registry status
- 1,040
- Enrollment target
- 4
- Study locations
NCT04467489: Active study of Cerebral Cavernous Malformation and Cavernous Angioma, sponsored by University of Chicago.
NCT04467489 is a study of Cerebral Cavernous Malformation and Cavernous Angioma that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 1,040 participants. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04467489, a study of Cerebral Cavernous Malformation and Cavernous Angioma, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- 1,040 participants
- Enrollment target
- 4
- Study locations
Study Summary
The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.
Primary Outcome
To test whether individual and combined levels of candidate plasma proteins and miRNAs can be associated with diagnosis of CASH (cross sectional) and can predict/prognosticate future SH (longitudinal) in CAs
Conditions Studied
Interventions
- OTHER observational
Study Locations (4)
Arizona
- Barrow Neurological Institute at St. Joseph's Hospital and Medical Center - Phoenix
California
- University of California, San Francisco - San Francisco
Illinois
- The University of Chicago Medical Center - Chicago
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,040 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2026-06-30 |
What the registry record for NCT04467489 still lists
NCT04467489 is an observational study that tracks outcomes without assigning an intervention. Its 1,040 participants enrollment target places it among the larger protocols in the corpus.
The record links to 3 conditions, with Cerebral Cavernous Malformation appearing as the primary indexed condition, and to 1 intervention - of which observational is the first listed.
NCT04467489 reports a single indexed study location in Arizona, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT04467489 about?
NCT04467489 is a clinical study titled "Biomarkers of CASH". The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the...
What is the current status of trial NCT04467489?
This trial is currently active not recruiting. The enrollment target is 1,040 participants. The study started on 2020-05-22. Estimated completion is 2026-06-30.
What conditions does trial NCT04467489 study?
This clinical trial studies the following conditions: Cerebral Cavernous Malformation, Cavernous Angioma, Hemorrhagic Microangiopathy.
What interventions are being tested in trial NCT04467489?
The interventions under investigation include: observational (OTHER).
Who is sponsoring clinical trial NCT04467489?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04467489 being conducted?
This trial has 4 study locations across Arizona, California, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Cavernous Malformation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
- NCT06661720 · 1,040 participants · Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI